Multiple Myeloma Hub
Multiple Myeloma Hub
  • 443
  • 109 311
Q&A | How to sequence CAR T-cell therapy and bispecific antibodies in R/R MM
This symposium closed with a panel Q&A session with live audience participation, where our panelists shared their perspectives on how to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma.
This independent educational activity was supported by Bristol Myers Squibb. All content was developed independently by the faculty.
Переглядів: 187

Відео

Q&A | Next wave of immune-based therapies in R/R MM
Переглядів 80Місяць тому
This symposium closed with a panel Q&A session with live audience participation, where our panelists shared their perspectives on the next wave of immune-based therapies in relapsed/refractory multiple myeloma. This independent educational activity was supported by Bristol Myers Squibb. All content was developed independently by the faculty.
Symposium | Next wave of immune-based therapies: What you need to know, which focused on R/R MM
Переглядів 279Місяць тому
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’. Here the Multiple Myeloma Hub is pleased to share the session: Next wave of immune-based therapies: What you need to know, which focused on relapsed/refractory (R/R) multiple myeloma...
Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in R/R multiple myeloma
Переглядів 406Місяць тому
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’. Here, the Multiple Myeloma Hub is pleased to share the session, which covered how to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory (R/R) multiple myelo...
Iberdomide - efficacy and safety in RRMM
Переглядів 2342 місяці тому
Sagar Lonial reviews the efficacy and safety profile of iberdomide in RRMM, including key findings to date, ongoing trials, future directions, and potential clinical implications. Lonial begins by outlining how both iberdomide and mezigdomide are novel cereblon E3 ligase modulators (CELMoDs), which bind cereblon more potently than previous agents such as lenalidomide or pomalidomide. He describ...
Infections associated with bispecific antibodies (Q&A)
Переглядів 602 місяці тому
Following her presentation, Beksaç chaired a Q&A session featuring Hermann Einsele, Heinz Ludwig, María-Victoria Mateos, Paul Richardson, Vania Tietsche de Moraes Hungria, and Elena Zamagni. Discussions included the challenges associated with COVID infections, the need for vaccination of donors for intravenous immunoglobulin treatment, and the impact of dosing schedules on reducing infectious c...
Infections associated with bispecific antibodies
Переглядів 1532 місяці тому
During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, leading experts met to discuss key considerations regarding infections associated with bispecific antibodies. Meral Beksaç opened with a presentation reviewing the infectious complications associated with bispecific antibodies and current treatment algorithms for such infections. Beksaç explored an analysis of infections an...
Current use of CAR T-cell therapies in clinical practice - Q&A
Переглядів 852 місяці тому
Following his presentation, Einsele chaired a Q&A session featuring Paul Richardson, Heinz Ludwig, María-Victoria Mateos, Meral Beksaç, Elena Zamagni, and Vania Tietsche De Moraes Hungria. Discussions included the implementation of CAR T-cell therapies in earlier lines of therapy, CAR T-cell therapies in high-risk disease, maintenance after CAR T-cell therapies, and toxicities with CAR T-cell t...
Current use of CAR T-cell therapies in clinical practice
Переглядів 3672 місяці тому
During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current use of CAR T-cell therapies in clinical practice, with a focus on patient-specific considerations in the development of personalized treatment plans. To open, Hermann Einsele provides a presentation reviewing the latest data from trials of ciltacabtagene autoleucel (cilta-cel) ...
How might AI be incorporated into the diagnosis and management of MM?
Переглядів 953 місяці тому
During the 5th European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with Adrián Mosquera Orgueira, University of Santiago de Compostela, Santiago, ES. We asked, How might artificial intelligence (AI) be incorporated into the diagnosis and management of multiple myeloma? Adrián Mosquera Orgueira opens by emphasizing the importance of standardization of both diagnostic ...
What are the latest updates to the NCCN guidelines for the management of MM?
Переглядів 3044 місяці тому
During the 5th European Myeloma Network (EMN) Meeting, the Multiple Myeloma Hub was pleased to speak with Shaji Kumar, Mayo Clinic, Rochester, US. We asked, What are the latest updates to the National Comprehensive Cancer Network (NCCN) guidelines for the management of multiple myeloma? In this interview, Shaji Kumar provides an overview of the updates to the NCCN guidelines pertaining to the d...
What is the rationale for T-cell therapies in the treatment of smoldering MM?
Переглядів 2355 місяців тому
During the International Myeloma Society 5th Immune Effector Cell Workshop, the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked, What is the rationale for T-cell therapies in the treatment of smoldering MM? In this interview, Irene Ghobrial discusses the rationale for the use of immunotherapies in smoldering multiple myeloma (MM). ...
What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?
Переглядів 495 місяців тому
The Multiple Myeloma Hub and Lymphoma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the rationale for monitoring secondary malignancies after B-cell maturation antigen (BCMA) and CD19 chimeric antigen receptor (CAR) T-cell therapy? In this interview, Anna Sureda discusses the latest data on the incidence of secondary malignancies after...
Symposium | Introduction to T-cell engagers and general mechanism of action
Переглядів 2065 місяців тому
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023.” This live symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt. Lonial opened the symposium with a welcome and introduction to T-cell-engaging bispec...
Symposium | BCMA-directed bispecific antibodies
Переглядів 1915 місяців тому
During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on B-cell maturation antigen (BCMA)-directed bispecific antibodies in multiple myeloma (MM). Bumma provided an overview of T-cell engagement ...
Symposium | Practical management of adverse events with immunotherapies
Переглядів 1545 місяців тому
Symposium | Practical management of adverse events with immunotherapies
Symposium | Looking to the future of bispecific antibodies in MM
Переглядів 2135 місяців тому
Symposium | Looking to the future of bispecific antibodies in MM
Symposium | Q&A session
Переглядів 1225 місяців тому
Symposium | Q&A session
Symposium | Beyond BCMA: Novel strategies using bispecific antibodies
Переглядів 1695 місяців тому
Symposium | Beyond BCMA: Novel strategies using bispecific antibodies
What factors contribute to resistance to BCMA-targeted CAR T-cell therapies in multiple myeloma?
Переглядів 726 місяців тому
What factors contribute to resistance to BCMA-targeted CAR T-cell therapies in multiple myeloma?
What are the management strategies for CRS and ICANS in MM?
Переглядів 927 місяців тому
What are the management strategies for CRS and ICANS in MM?
What are the latest updates on trispecific antibodies for the treatment of MM?
Переглядів 3847 місяців тому
What are the latest updates on trispecific antibodies for the treatment of MM?
What are the real-world outcomes following treatment with teclistamab in RRMM?
Переглядів 1807 місяців тому
What are the real-world outcomes following treatment with teclistamab in RRMM?
How do response rates observed in clinical trials translate into real-world outcomes in MM?
Переглядів 1287 місяців тому
How do response rates observed in clinical trials translate into real-world outcomes in MM?
Are CAR T-cell therapies effective in the treatment of extramedullary MM?
Переглядів 2158 місяців тому
Are CAR T-cell therapies effective in the treatment of extramedullary MM?
How does treatment with ide-cel impact quality of life in RRMM?
Переглядів 768 місяців тому
How does treatment with ide-cel impact quality of life in RRMM?
What is the impact of dexamethasone dose strength on outcomes in NDMM?
Переглядів 2408 місяців тому
What is the impact of dexamethasone dose strength on outcomes in NDMM?
Patient case discussion on treating with CELMoDs
Переглядів 1979 місяців тому
Patient case discussion on treating with CELMoDs
For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?
Переглядів 13810 місяців тому
For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?
For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?
Переглядів 5910 місяців тому
For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?

КОМЕНТАРІ

  • @fatherabdul
    @fatherabdul Місяць тому

    Super

  • @SoheilaLapeyre-wm7sd
    @SoheilaLapeyre-wm7sd 3 місяці тому

    Is it available in San Francisco ?

  • @sfeeneygirl
    @sfeeneygirl 3 місяці тому

    Thank you

  • @orscrub3161
    @orscrub3161 7 місяців тому

    how do you explain MM progressing to PCL just 5 months after CAR T Cell Therapy??

  • @SMC2016
    @SMC2016 7 місяців тому

    Please advise what to do if Darzalex 11 week immunotherapy doesnt work after a quick relapse. Please advise . . .

  • @emmanuelking9988
    @emmanuelking9988 8 місяців тому

    I have multiple myeloma...thank you for mentioning cancer patients wanting to "make their doctor happy" by not fully disclosing their symptoms and going along the "everything is going well" theater. I sometimes do this because it actually makes my life easier, it's more of a mental health protection for me because doctors can start gaslighting you or pressure you on treatments you don't understand or are ready for. Anyway, this is why it's very important to educate yourself on your diagnosis and treatment and be your own advocate, do your own research and follow up that research with lots of questions. May God grant all those with cancer healing and health 🙏

  • @justincase1575
    @justincase1575 9 місяців тому

    I am experiencing pain with treatment that no one wants to admit that I have. I am told how well I’m responding and should feel ok. I also have a bad heart with a 30 year old bypasses all but one plugged. I know everyone wants to make me feel better but I’m the one in pain!

    • @marywilliams9858
      @marywilliams9858 2 місяці тому

      Speak up dear. I wrote up a doctor twice for withholding pain medication and now I am handled with kid gloves. Put your concerns in writing. Wrote to his boss or to the hospital where he works. One doctor told me: "You are very smart...." He looked nervous.

    • @marywilliams9858
      @marywilliams9858 2 місяці тому

      He made me so desperate I overdosed.

  • @eryilkce
    @eryilkce 9 місяців тому

    Hi, can you confirm T(4,11) or was T(11,14) meant, please?

  • @emekaihunwo3630
    @emekaihunwo3630 10 місяців тому

    It was a blessing to have met with you Dr Igudia,UA-cam you have brought up a huge smile on my face and it's gonna be permanent, because I never thought I would ever be cured of herpes infection,all I could say now is thank you Dr

  • @timlittle1286
    @timlittle1286 10 місяців тому

    Sometimes diet can increase the intensity of pain if something in the diet causes inflammation.

  • @junedolson1642
    @junedolson1642 11 місяців тому

    Great explanation, thank you

  • @janjans1178
    @janjans1178 Рік тому

    I slowed the video on playback - works well!

  • @doctork1708
    @doctork1708 Рік тому

    I don’t have any desire to please anyone especially a physician, but I’m sick of being ignored and gaslit by physicians. It took years for a correct diagnosis b because of incompetent and uncaring physicians. They stole my quality and duration of my life.

  • @elainerobertson1988
    @elainerobertson1988 Рік тому

    Excellent - thank you Sir.

  • @nagarajarao.k.v.8761
    @nagarajarao.k.v.8761 Рік тому

    Dear doctor I have intense itch on leg litchen amylodisis doctor told tried all medicine 5year nothing going whther skin amylodisis effect heart kidney liver jagannath bangalore india

  • @BerndWichtlhuber
    @BerndWichtlhuber Рік тому

    Very interesting findings. Thanks for sharing. My asian wife is treated with Dara-VtD for her multiple myeloma at present. Very promising results so far (IGA Kappa, Biopsy less than 5% (after 90%) still in cycle 1). Thanks for your relentless efforts.

  • @clonekrilin5151
    @clonekrilin5151 2 роки тому

    you need to adjust the content

  • @marcinrokosz2162
    @marcinrokosz2162 2 роки тому

    「明確なメッセージ、明確な構造、理解しやすい、ありがとう」、

  • @amikastavri2826
    @amikastavri2826 2 роки тому

    you need to adjust the content

  • @ameterasu13
    @ameterasu13 2 роки тому

    Does MGUS complicate to Waldenstrom Macroglobulinemia??

  • @user-jsfa5333
    @user-jsfa5333 2 роки тому

    Salut je veux telephone ou mail du professeur mohamed mohty

  • @delta191365
    @delta191365 2 роки тому

    How does mgus affect the eyes?

  • @jerryserrano5062
    @jerryserrano5062 2 роки тому

    My calcium fluctuates every 3 months at my checkups. 9,12,,10,13. My protein does the same

  • @bashirbadamasi7035
    @bashirbadamasi7035 2 роки тому

    I have been completely cured of diabetes and I no longer depend on injecting insulin.dr Emuakhe on UA-cam has don it with his great herbs.m very great full for that,I really want to live and share this with my family

  • @gaybriellookingland6756
    @gaybriellookingland6756 2 роки тому

    2019 !

  • @bad_manbot
    @bad_manbot 2 роки тому

    thank you for this informative summary

  • @melvicmakeup6677
    @melvicmakeup6677 3 роки тому

    Would you recommend someone who is 44, has an M protein Lambda 4.5, with some CRAB features? Thank-you

  • @elisaben3120
    @elisaben3120 3 роки тому

    Can we carry the MM for as longue as 13 years without knowing it. Thank you

  • @elisaben3120
    @elisaben3120 3 роки тому

    Dr i have been diagonised by MM in 2019. I believe and i am sur that this MM have begun to develop in my body since 2008. I have seek help ever since because of the strange symptoms i have spoke about this symtomps ever since. My GP ignored my paine and suffering. I knew somthing bad is going on in my body. In 2014/2015 they said i had cancer later on 6 months later they said every thing went to normal. I find that stange and warying but i was happy yet the pain and sufferying never stopped only on 2019 when i did for the first IRM because i had to tape in the taple in order to for the GP to take me seriously. They tald my it was sciatica and i shouldn't warry that much. Please Dr can you tell me at what stage of the illness that the Dr should take the patient seriousely that wasn't in Germany nor France but in a very advance and well informed country prouding themself of been at the top level of medical knowledge.

  • @karanlaurie5355
    @karanlaurie5355 3 роки тому

    contact him on Instagram salami healing herbs check that up on Instagram.

  • @Isabelitamellamo
    @Isabelitamellamo 3 роки тому

    Would you also say that to ypung patients?

  • @jat8552
    @jat8552 3 роки тому

    Great info. Thank you!!!

  • @basimbahlis8680
    @basimbahlis8680 3 роки тому

    Bonjourno

  • @МарьяКрасничкина

    0:41 Music ua-cam.com/video/ZPklRNjf2y4/v-deo.html

  • @lifeandamyloidosis8551
    @lifeandamyloidosis8551 4 роки тому

    I agree with all you say. I would add that the cost of therapies is however inflated by numerous systems that accept these inflated costs. I find it awkward to mention that us Multiple Myeloma patients, some who can not work, cost the system a million of dollars. I don't know that that is an appropriate calculation of costs. My oncologists and other specialists have revenus of half a million per year, our therapies are bought and sold for half a million dollars and we should shoulder an economic equation that equals a million dollars. I don't agree with that math. I don't know if I am clear in my comment. I worked all my life and I am raising two children and taking care of others...where does that fit in - in the calculation of costs? I don't agree with CAR T costs, or Velcade costs or whatever...they are inflated.

  • @Music-qd8qn
    @Music-qd8qn 4 роки тому

    Multiple Myeloma Hub

  • @Enygma293
    @Enygma293 4 роки тому

    C’est mon papou :)

  • @marantzcd1
    @marantzcd1 5 років тому

    Good info.

  • @carmenmarino5909
    @carmenmarino5909 5 років тому

    Giovanotti ate

  • @rickrosenbloom9605
    @rickrosenbloom9605 6 років тому

    Excellent points Vincent.

  • @bettyboop0694
    @bettyboop0694 6 років тому

    On entend rien ! vidéo inutile